JP6270848B2 - ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 - Google Patents

ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 Download PDF

Info

Publication number
JP6270848B2
JP6270848B2 JP2015529881A JP2015529881A JP6270848B2 JP 6270848 B2 JP6270848 B2 JP 6270848B2 JP 2015529881 A JP2015529881 A JP 2015529881A JP 2015529881 A JP2015529881 A JP 2015529881A JP 6270848 B2 JP6270848 B2 JP 6270848B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
compound
alkyl
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015529881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528463A (ja
JP2015528463A5 (enExample
Inventor
ワ ビン イム
ワ ビン イム
バーク　ロバート　エム
ロバート エム バーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2015528463A publication Critical patent/JP2015528463A/ja
Publication of JP2015528463A5 publication Critical patent/JP2015528463A5/ja
Application granted granted Critical
Publication of JP6270848B2 publication Critical patent/JP6270848B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015529881A 2012-08-27 2013-08-23 ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 Expired - Fee Related JP6270848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693437P 2012-08-27 2012-08-27
US61/693,437 2012-08-27
PCT/US2013/056418 WO2014035827A1 (en) 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (3)

Publication Number Publication Date
JP2015528463A JP2015528463A (ja) 2015-09-28
JP2015528463A5 JP2015528463A5 (enExample) 2016-10-13
JP6270848B2 true JP6270848B2 (ja) 2018-01-31

Family

ID=49117974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529881A Expired - Fee Related JP6270848B2 (ja) 2012-08-27 2013-08-23 ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下

Country Status (11)

Country Link
US (2) US9024042B2 (enExample)
EP (1) EP2888239B1 (enExample)
JP (1) JP6270848B2 (enExample)
KR (2) KR20200110820A (enExample)
CN (1) CN104684904B (enExample)
AU (1) AU2013309124B2 (enExample)
CA (1) CA2882743C (enExample)
DK (1) DK2888239T3 (enExample)
ES (1) ES2711425T3 (enExample)
TR (1) TR201900863T4 (enExample)
WO (1) WO2014035827A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509610A (ja) * 2014-02-20 2017-04-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684904B (zh) 2012-08-27 2017-10-13 阿勒根公司 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
WO2015175544A1 (en) * 2014-05-12 2015-11-19 Allergan, Inc. Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs
US9573926B2 (en) 2014-05-22 2017-02-21 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
WO2016054596A1 (en) * 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DE10322843A1 (de) 2003-05-19 2004-12-16 Clariant Gmbh Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
WO2006047466A2 (en) * 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
BRPI0714885B8 (pt) * 2006-07-11 2021-05-25 Allergan Inc compostos terapêuticos e seu uso
US7947732B2 (en) 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
AU2009246573B2 (en) * 2008-05-15 2014-04-24 Allergan, Inc. Therapeutic substituted cyclopentanes
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CN104684904B (zh) 2012-08-27 2017-10-13 阿勒根公司 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509610A (ja) * 2014-02-20 2017-04-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少

Also Published As

Publication number Publication date
DK2888239T3 (en) 2019-03-04
CA2882743C (en) 2021-11-30
US9024042B2 (en) 2015-05-05
KR102304111B1 (ko) 2021-09-23
US20140057975A1 (en) 2014-02-27
KR20150046269A (ko) 2015-04-29
US20150322036A1 (en) 2015-11-12
KR20200110820A (ko) 2020-09-25
JP2015528463A (ja) 2015-09-28
CN104684904B (zh) 2017-10-13
EP2888239B1 (en) 2018-11-28
WO2014035827A1 (en) 2014-03-06
HK1211031A1 (en) 2016-05-13
AU2013309124A1 (en) 2015-03-12
AU2013309124B2 (en) 2018-03-01
US9427401B2 (en) 2016-08-30
CN104684904A (zh) 2015-06-03
EP2888239A1 (en) 2015-07-01
CA2882743A1 (en) 2014-03-06
ES2711425T3 (es) 2019-05-03
TR201900863T4 (tr) 2019-02-21

Similar Documents

Publication Publication Date Title
JP6270848B2 (ja) ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下
JP6626831B2 (ja) ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少
US9090595B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
JP6662864B2 (ja) ガンマ−ラクタムのエステルプロドラッグ及びそれらの使用
HK1211031B (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
HK1229812A1 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171226

R150 Certificate of patent or registration of utility model

Ref document number: 6270848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees